Mindset Pharma Inc. announced that it has filed two international patent applications under the Patent Coorperation Treaty ("PCT") for the protection of certain of Mindset's non-hallucinogenic novel non-tryptamine compounds known as "Family 6." The filings are based on pre-clinical studies and provide Mindset with preliminary freedom to operate for all claimed drug candidates from Family 6. The pre-clinical study results underpinning the candidates identified in these patent applications are highly promising. Work performed on these novel non-tryptamine candidates, which included in-vitro screening, and ADME (absorption, distribution, metabolism, and excretion), along with in vivo studies, indicates 5-HT2A serotonin receptor activation without the cardinal in vivo signs of a hallucinogenic effect. While some Family 6 compounds are functionally more potent than psilocybin and 5-MeO-DMT as 5-HT2A agonists, these drug candidates elicited only a modest or no head muscle response, suggesting a non-hallucinogenic effect profile.
1st Jan change | Capi. | |
---|---|---|
+17.96% | 44.96B | |
+1.17% | 42.65B | |
+48.77% | 41.85B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |